Cover Image

Renal cell carcinoma: evolving approaches to advanced non-clear cell carcinoma

Daniel Y.C. Heng, Ronald M. Bukowski
  • Daniel Y.C. Heng
    Experimental Therapeutics, Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, United States | bukowsr@ccf.org
  • Ronald M. Bukowski
    Experimental Therapeutics, Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, United States

Abstract

The treatment of metastatic renal cell carcinoma (RCC) has changed dramatically with the introduction of targeted therapies including sunitinib, sorafenib, and temsirolimus. Because patients with conventional clear cell histology account for 75- 80% of all patients with RCC, there has been little accumulated evidence on the treatment of patients with non-clear cell histologies. Most clinical trials have excluded them from enrolment, except for randomized studies investigating temsirolimus. Many retrospective studies on the use of all three of these targeted therapies in patients with non-clear cell histology have demonstrated response rates ranging from 3.7%–16%. Although response rates may not be as high compared to patients with clear cell histologies, targeted therapy does provide a clinically meaningful response.

Keywords

Renal cell cancer - Non-clear cell - Papillary - Chromophobe - Collecting duct - Sunitinib - Sorafenib - Temsirolimus

Full Text:

FULL TEXT
Submitted: 2011-12-18 12:48:58
Published: 2011-12-18 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
360

Views:
FULL TEXT
94

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2011 Daniel Y.C. Heng, Ronald M. Bukowski

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185